Abstract Number: 2458 • 2019 ACR/ARP Annual Meeting
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of the spondylarthropathies. It is associated with psoriasis and typically seronegative for autoantibodies. PsA disease activity can…Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…Abstract Number: 649 • 2018 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in patients with axial spondyloarthritis (axSpA). According to the…Abstract Number: 1326 • 2018 ACR/ARHP Annual Meeting
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…Abstract Number: 1954 • 2017 ACR/ARHP Annual Meeting
Association of CRP with BMI in Males and Females
Background/Purpose: C-reactive Protein (CRP) is an inflammatory marker commonly used to help aid in diagnosis, assess disease activity or monitor response to therapy. It is…Abstract Number: 2117 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks. Attacks are accompanied by substantial increase in acute phase reactants such…Abstract Number: 2212 • 2017 ACR/ARHP Annual Meeting
A Metabolite of C-Reactive Protein, a Marker of Disease Actvity, Is Prognostic of Radiographic Knee OA
Background/Purpose: There are two major needs in clinical DMOAD development: Identifying a population with an active and progressive disease to demonstrate significant improvements by an…Abstract Number: 2423 • 2017 ACR/ARHP Annual Meeting
Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) was identified with active disease (confirmed by Power Doppler ultrasound (PDUS)) but normal levels…Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…Abstract Number: 537 • 2017 ACR/ARHP Annual Meeting
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »